| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | VCAM1; L1CAM; Vascular cell adhesion protein 1; V-CAM 1; VCAM-1; INCAM-100; CD antigen CD106 |
| Entrez GeneID | 7412 |
| WB Predicted band size | Calculated MW: 81 kDa; Observed MW: 110 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of VCAM1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于VCAM1抗体的参考文献示例(内容为虚构，仅作格式参考)：
1. **"VCAM1 mediates leukocyte-endothelial adhesion in atherosclerosis"**
*作者：Cybulsky MI, Gimbrone MA*
摘要：研究通过VCAM1抗体阻断实验，证明VCAM1在动脉粥样硬化斑块形成中促进单核细胞黏附到激活的内皮细胞，提示其作为治疗靶点的潜力。
2. **"Anti-VCAM1 antibody inhibits tumor metastasis via blocking endothelial adhesion"**
*作者：Gorski KS, Ramos TN*
摘要：在黑色素瘤小鼠模型中，使用VCAM1抗体阻断肿瘤细胞与血管内皮的相互作用，显著减少肺转移，表明靶向VCAM1可抑制癌症转移。
3. **"VCAM1 antibody-based detection of endothelial activation in sepsis"**
*作者：Zhang L, et al.*
摘要：开发高特异性VCAM1单克隆抗体，用于检测脓毒症患者血清中可溶性VCAM1水平，证实其与内皮损伤和疾病严重程度的相关性。
4. **"Targeting VCAM1 in autoimmune encephalomyelitis"**
*作者：Engelhardt B, Ransohoff RM*
摘要：通过VCAM1抗体干预实验性自身免疫性脑脊髓炎(EAE)模型，发现阻断VCAM1可减少T细胞向中枢神经系统的浸润，缓解神经炎症。
(注：以上文献信息为模拟内容，实际引用需核实真实出版物。)
VCAM1 (Vascular Cell Adhesion Molecule 1), also known as CD106. is a cell surface glycoprotein belonging to the immunoglobulin superfamily. It is primarily expressed on activated endothelial cells, macrophages, and certain stromal cells. VCAM1 mediates leukocyte adhesion and transmigration by interacting with integrin α4β1 (VLA-4) on immune cells, playing a critical role in inflammatory responses, immune surveillance, and leukocyte recruitment to sites of injury or infection. Its expression is upregulated by pro-inflammatory cytokines like TNF-α and IL-1β, making it a key biomarker in chronic inflammation, atherosclerosis, and cancer metastasis.
VCAM1 antibodies are tools designed to detect or modulate VCAM1 activity. In research, they are widely used in techniques such as flow cytometry, immunohistochemistry, and Western blotting to study VCAM1 expression patterns in disease models. Function-blocking VCAM1 antibodies can inhibit leukocyte-endothelial interactions, providing insights into inflammatory pathways or testing therapeutic strategies. Conversely, agonist antibodies may simulate VCAM1 signaling to explore its downstream effects.
Clinically, VCAM1 antibodies have potential therapeutic applications. For example, they are investigated for treating inflammatory disorders, autoimmune diseases, or preventing cancer spread by targeting VCAM1-mediated cell adhesion. However, their development faces challenges, including specificity and off-target effects. Overall, VCAM1 antibodies remain vital for both understanding vascular biology and advancing targeted therapies.
×
